Onco Actu du 23 avril 2015

	3. Prévention
Parsing The Latest Evidence That Aspirin And Coffee Keep Cancer Away [Forbes] The bottom line: Maintaining a daily coffee-and-aspirin routine probably isn’t harmful, but it’s way too early to say it will protect anyone from cancer.
	3.1 Tabac
New Orleans Bars Issue Last Call for Smoking [NY Times] “All right guys, put ’em out,” he said. “Sorry, it’s over.” Just after midnight, it became illegal to smoke in bars in New Orleans.
	4. Dépistage, diagnostic et pronostic
Study finds that microinjection platform enables assessment of multiple cancer drugs directly in tumors, predicts systemic response [Fred Hutch] Results from first-in-human study in lymphoma patients confirm feasibility for toxicity-sparing assessment of drug efficacy in cancer patients
To Find Combos, Presage Debuts Drug-Test Device In Cancer Patients [Xconomy] Some of the company’s promotional materials look to the day when oncologists use CIVO to help shape a cancer patient’s drug regimen. But Caffo downplayed that scenario, saying right now CIVO is being developed to help make pharmaceutical R&D decisions—including at Presage, which hopes to build its own drug pipeline—not to help doctors make personalized medicine decisions.
Opinion: Predicting the Efficacy of Cancer Immunotherapy [The Scientist] T-cell receptor repertoires could help researchers determine whether a certain treatment will work for a given cancer patient.
Personalized Devices Predict Cancer Drug Response [The Scientist] Two teams have developed tumor-implantable drug delivery devices to study real-time responses to multiple therapies in cancer patients.
	4.12 Biopsies liquides
The Future of Cancer Treatment is (Almost) Here [WIRED] Many more clinical trials need to be done and millions of dollars still need to be invested. But eventually, we’ll begin to match specific clinical outcomes, such as therapy response, with the circulating DNA that is sequenced.
	4.2 Dép., diag. & prono. - Génome
Are We Ready For Inexpensive, Patient Directed Genetic Testing For Breast Cancer? [Dr Len] There is much we don't know about how all of this is going to play out. Will it be a true disruptor, a view into the world to come? Or will it be a giant headache, full of unintended negative (and yes, positive) consequences?
	4.9 Dép., diag. & prono. - Sein
Why Many Doctors Don't Follow 'Best Practices' [NPR] Imagine, for example, that a healthy, 40-year-old woman walks into your office and asks about a mammogram. "If that woman were to develop breast cancer or to have breast cancer, you can imagine what might happen to you if you didn't order the test," Wu says. "Maybe you'd get sued."
On Mammography, Evidence, And Why We Need To Improve Breast Cancer Screening [Forbes] Perhaps the most accurate assessment of mammography today is that we just don’t have or know the numbers. The fact is, there is no good trial of mammography using current radiology systems in the context of modern pathology and minimalist treatment approaches. And there is none underway.
	5. Traitements
Toxic Mushroom-Based Drug May Help Battle Colorectal Cancer [MD Anderson Cancer Center] MD Anderson Study Reveals Role of Gene Called POLR2A.
Coffee could make breast cancer drug tamoxifen more effective [NHS Choices] Although the results of this study are interesting, it cannot prove that coffee has an effect on breast cancer, as other factors, called confounders, could have influenced the results.
	5.2 Pharma
Cancer drugs help Roche quarterly sales beat forecasts [Reuters] Investors are eager to see how rapidly it will file its so-called PD-L1 immunotherapy drug MPDL3280A for approval to treat patients with lung cancer, with some analysts predicting a submission by mid-year.
Roche buoyed by cancer drug sales [Pharmafile] Roche chief executive Severin Schwan says: “We started the year with strong growth and good uptake of new products. In particular, I am pleased to see continued strong demand for Perjeta for breast cancer".
ARIAD Announces Issuance of Key U.S. Patent on Brigatinib [ARIAD] The patent provides composition-of-matter protection through at least December 30, 2030 for ARIAD’s investigational ALK inhibitor, brigatinib. Additional patent applications covering brigatinib are pending in the U.S. and in other countries.
NATURE Publication: Breakthrough Development in Cancer Immunology [BioNTech AG] The article entitled “Mutant MHC II epitopes drive therapeutic immune responses to cancer” describes a novel immunological principle relevant to cancer immunotherapy and how this translates into patient specific mRNA cancer vaccines targeting multiple mutations.
	5.2.1 Pharma - Partenariats
Bayer supports cancer biomarker research in Europe [Bayer] Bayer HealthCare and University Medical Center Hamburg-Eppendorf are the main coordinators of the international consortium to validate blood-based biomarker technologies.
	5.3 Traitements - FDA, EMA,...
FDA Willing to Accept Different Endpoints When Assessing Lung Cancer Drugs [RAPS] The final guidance document, Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics, is intended to clarify the evidence FDA is willing to accept in the review of new NSCLC drugs.
	5.9 AACR
AACR 2015: Report from Day 5 [Cancer Research Institute Blog] We heard a lot earlier in the week about the important role of T cells—both natural and genetically modified—in fighting cancer. But T cells cannot do their job alone. Many other cell types play a role in supporting and, in some cases, repressing the immune response.
A Sampling of Promising Cancer Science Highlighted at AACR Annual Meeting [Memorial Sloan Kettering Cancer Center] - Targeting Epstein-Barr Virus to Treat a Lethal Transplant Complication - Drug Blocks Hormones Fueling Breast Cancer Growth - Combination Immunotherapy Works Better than Single Drug for Melanoma
	5.9.6 AACR - prostate
'Targeted' ovarian cancer drug could also help certain men with prostate cancer [Cancer Research UK] "The trial is also exciting because it shows that PARP inhibitors can be effective in a wider group of patients than had been thought - in men as well as women, patients with mutations in their tumours as well as those with inherited mutations, and in those with a wider range of gene defects than just BRCA mutations."
	6. Lutte contre les cancers
Worry may drive low-risk cancer patients to want double mastectomy [Reuters] The women whose questionnaires showed they had less cancer knowledge and greater worry tended to be more interested in prophylactic mastectomy, and those who were more worried were more likely to ultimately have the procedure.
	6.1 Observation
Two in three cancer sufferers have other health conditions [The Telegraph] “People have individual and complex needs and our health and social care system urgently needs to reflect this. We need to care for the whole person, not just treat single diseases and their individual symptoms separately.”
	6.11 Patients
Survivor, Hero, Battle: The Complicated Language of Cancer [Dana-Farber Cancer Institute] “I feel like the term survivor is so confusing,” remarked one young adult. “Dying isn’t losing; cancer isn’t a game.”
	6.6 Publications
Are metrics meaningful? [BioMed Central blog] How do we measure the impact of research? And are the metrics we measure of value? These questions, and more, were discussed at this year’s COPE European Seminar.
	6.7 DMP, Big Data & applis
Apps Built on Apple’s Health Platform Will Offer Medical Advice, Thanks to IBM [MIT Technology Review] Apple helped IBM create a service that can analyze medical data collected by iPhone apps, and could deliver personalized health advice.